People with myasthenia gravis, particularly women, have a high symptom burden that considerably affects their health-related quality of life, but the disease’s human cost is rarely given adequate study, a systematic literature review has found. Symptoms generally eased following treatment and disease remission. Still, there is…
Medison Pharma has entered into a pact with the global immunology company Argenx to bring efgartigimod to market in Israel and across several European countries for treating adult patients with generalized myasthenia gravis (gMG). The agreement sets the stage for commercialization of efgartigimod in 14 countries: Hungary, Poland, Czech…
Vyvgart (efgartigimod alfa-fcab) is being made available to eligible adults with generalized myasthenia gravis (gMG) in the U.K. under an early access to medicines scheme (EAMS), Argenx, the therapy’s developer, announced. An EAMS is designed to enable access to potentially lifesaving medications for patients with unmet medical…
Myasthenia gravis (MG) affects 20 of every 100,000 people, according to the Myasthenia Gravis Foundation of America (MGFA), which is working to help educate the public about the rare disorder as part of this year’s MG Awareness Month. MG typically affects women under the age of 40 and…
A woman with repeat myasthenia gravis (MG) flares was found to have several rare and benign tumors in her heart, a case study reported. According to its scientists, this case highlights the importance of cardiac evaluations of MG patients, particularly those with recurring episodes of myasthenia…
A man developed myasthenia gravis (MG), which quickly progressed to an advanced stage, shortly after surgery to remove a tumor in the thymus gland, according to a report from China. Post-surgical MG is rare and its rapid severity even rarer, its scientists noted, and this man’s MG diagnosis was more…
A woman was diagnosed with both ocular myasthenia gravis (MG) and a hereditary form of motor neuropathy, a condition affecting the nerves controlling the muscles in the body, according to a case report from China. The report, “Myasthenia gravis coexisting with HINT1-related motor axonal neuropathy without neuromyotonia: a…
The Pfizer-BioNTech and the Moderna mRNA COVID-19 vaccines may, in very rare cases, cause myasthenia gravis (MG) symptoms to worsen in people with more severe disease, a small Japanese study reported. The study, “Flare of myasthenia gravis induced by COVID-19 vaccines,” was published in the Journal of…
Descartes-08, Cartesian Therapeutics’ investigational CAR T-cell therapy, appears generally safe and markedly lessened symptom severity in the first five patients with generalized myasthenia gravis (gMG) enrolled in a Phase 1b/2a clinical trial. “I am very encouraged by the interim analysis findings,” as the therapy “appears safe and well…
Both zilucoplan and rozanolixizumab, UCB’s experimental therapies for generalized myasthenia gravis (gMG), safely and effectively reduced symptom severity and their impact on daily activities, while improving patients’ quality of life, top-line data from two Phase 3 trials show. Zilucoplan works by blocking the complement system, a part…
Get regular updates to your inbox.